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Substandard medicines are medicines which 
have failed to pass the quality measurements 
and standards set for them.1 They should be 
distinguished from counterfeit (falsified) 
medicines which are deliberately and fraud-
ulently mislabelled. Combining the two 
together however is not helpful. They are 
different problems that require different solu-
tions. Substandard and counterfeit medicines 
are a widespread problem in low-income and 
lower–middle-income countries. A systematic 
review showed that the median prevalence 
of substandard and counterfeit medicines 
was 28.5%.1 This ranged from 11% to 48% 
in individual studies. The 15 studies were 
all limited to antimicrobial drugs, with the 
majority (13) including antimalarials. Only 2 
of the 15 studies within the systematic review 
differentiated between substandard and 
counterfeit medicines. Both studies involved 
antimalarial drugs in South East Asia. They 
both found that counterfeit medicines were a 
greater problem than substandard medicines. 
The biggest problem in relation to the quality 
of the medicines tested was an inadequate 
amount of the active ingredient.
HIGH-INCOME COUNTRIES
Although the prevalence of substandard 
medicines in high-income countries is 
unknown, studies in both the UK and Canada 
show it is a significant issue.2 3 Contamination 
and stability issues were the major problems 
in Canada, whereas contamination is the 
major problem in the UK. There were 74 
cases of contamination of medicinal prod-
ucts within the UK over an 11-year period2 
and 139 incidents in Canada over a 9-year 
period.3 Counterfeit medicines were a minor 
problem, both in Canada and the UK. An 
increasing number of substandard medicines 
have been identified in both Canada and 
the UK over time, although this may be due 
to improved detection by regulatory agen-
cies. It is important to note that substandard 
medicines were not restricted to the manufac-
turers for generic medicines, but involved all 
the major pharmaceutical companies in both 
Canada and the UK.
The clinical impact of substandard medi-
cines is unknown. Contaminated drugs were 
however responsible for more than 120 deaths 
at a single hospital in Pakistan.4 Additionally, 
more than 700 individuals developed a fungal 
infection following the use of contaminated 
methylprednisolone in the USA, associated 
with at least 61 deaths.5 These events suggest 
that for high-income countries, substan-
dard medicines may be a greater problem 
clinically than counterfeit medicines. This 
may also be the situation in lower-income 
and lower–middle-income countries as illus-
trated by a study of the Medicines Quality 
Database (MQDB).6 MQDB is an online data-
base that documents medicines tested for 
quality in selected countries in Africa, Asia 
and South America.6 A recent study of over 
15 000 samples identified 848 samples (5.6%) 
as being of poor quality.6 The majority of 
the failed samples were substandard (767, 
90.4%). The remaining 81 (9.6%) were coun-
terfeit. Additional evidence suggesting that 
substandard medicines are a greater problem 
than counterfeit medicines is provided by the 
problems associated with diethylene glycol.
DIETHYLENE GLYCOL
Diethylene glycol is an industrial solvent. 
It was used as a solvent for sulfanilamide in 
the USA in the 1930s. There were over 100 
deaths including 34 children. This tragedy 
resulted in legislation in the USA to ensure 
that formulations of medicines were tested 
for safety.
Diethylene glycol poisoning results in 
gastrointestinal problems initially—nausea, 
vomiting, diarrhoea, abdominal pain and 
anorexia. Subsequently, a wide variety of 
symptoms may occur including weakness, 
lethargy, malaise, fever and restlessness. 
Central nervous system depression, seizures, 
metabolic acidosis, liver failure and acute 
renal failure can also develop.
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It has been used fraudulently in counterfeit medicines, 
which have resulted in the deaths of over 100 children.7 
It has also been found as a contaminant in substandard 
medicines and this has resulted in the deaths of over 200 
children in Haiti, Nigeria and India.7 There have also 
been cases of contamination of products in Spain and 
the USA. It is worth noting that more children have died 
from substandard medicines contaminated with dieth-
ylene glycol than counterfeit medicines where diethylene 
glycol has been used as a solvent.
HOW MANY SUBSTANDARD MEDICINES ARE ACCEPTABLE?
No system is perfect. It is inevitable that there will be 
substandard medicines just as there are other substan-
dard products. The question however is ‘What degree 
of substandard medicines are acceptable?’ Because a 
substandard medicine can result in a fatal outcome for 
the patient, the responsibility for minimising the occur-
rence of substandard medicines should be greater than 
that on the manufacturer of a non-essential consumer 
product. Data from the UK and Canada, alongside 
recent events in both Pakistan and the USA, suggest 
that substandard medicines are a significant problem 
and are not restricted to pharmaceutical products from 
middle-income countries or companies specialising in 
the manufacture of generic medicines. The data from 
Canada and the UK show that all companies are associ-
ated with substandard medicines. The pharmaceutical 
industry however needs to accept their responsibility for 
trying to ensure that substandard medicines are an infre-
quent occurrence.
RECOGNISING SUBSTANDARD MEDICINES
Health professionals need to be aware that medicines 
like any other product may be substandard. Counterfeit 
medicines may be recognised by spelling mistakes in the 
packaging. Recognising substandard medicines is more 
difficult. The possibility of a substandard medicine should 
be considered if: a patient fails to respond to treatment; 
if several patients who have received the same batch of a 
particular drug fail to respond to treatment; if an unusual 
adverse drug reaction occurs. For medicines adminis-
tered parenterally, unusual appearance or smell should 
raise suspicion that the medicine may be contaminated. 
Because of the difficulties in recognising substandard 
medicines, it is essential that the pharmaceutical industry 
does its utmost to minimise substandard medicines.
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